Intensity Therapeutics Reports Q3 2026 Financial Results and Clinical Trial Resumption
Intensity Therapeutics (INTS) reported third-quarter 2026 financial results characterized by increased research and development spending as the company resumes clinical enrollment for its sarcoma and breast cancer programs. The company recorded a net loss of $3.5 million, a 33% increase from the previous year, driven largely by higher R&D costs related to manufacturing and patient enrollment activities. Despite the widening losses, preliminary data from the INVINCIBLE-4 phase II breast cancer study showed promising results, with a 71% pCR rate for patients receiving INT230-6 compared to 42% for the standard of care. However, management cautioned that capital remains a significant constraint on the speed of clinical site activation and patient enrollment for the INVINCIBLE-3 study.
Tickers: $AAPL $AMZN $GOOG $INTS $IVT $META $MSFT $NVDA $TSLA
Topics: cash burn clinical trials earnings report net loss R&D expenses